#Trodelvy price

[tukysa]

HER2 METASTATIC BREAST CANCER & ITS NEW TREATMENT

HER2-positive metastatic breast cancer is a subtype of breast cancer where the cancer cells overexpress the HER2 protein, leading to more aggressive cancer growth and increased risk of metastasis.

There are several treatments available for HER2-positive metastatic breast cancer, including chemotherapy, targeted therapy, hormone therapy, and immunotherapy. One new treatment option is Tucatinib (Tukysa), which was approved by the US FDA in 2020. Tucatinib is a small molecule tyrosine kinase inhibitor that targets HER2, and it has shown promising results in clinical trials. In a phase 3 trial, the addition of tucatinib to standard treatment (trastuzumab and capecitabine) resulted in a significant improvement in progression-free survival and overall survival compared to standard treatment alone.

Other newer treatments that have been approved for HER2-positive metastatic breast cancer include trastuzumab deruxtecan (Enhertu), a HER2-targeted antibody-drug conjugate, and fam-trastuzumab deruxtecan-nxki (Zynlonta), another antibody-drug conjugate. Both drugs have shown promising results in clinical trials and have been approved for patients who have received at least two prior anti-HER2 treatments.

Trodelvy has been compared with standard treatment in one of the main studies, which had 529 patients with metastatic or locally advanced triple-negative breast cancer who received two or more prior systemic (whole-body) treatments, including at least one of them for advanced disease. Patients who took Trodelvy lived for an average of 4.8 months without cancer progression and getting it worse than as compared with 1.7 months for the patients who took standard treatment. Patients on Trodelvy lived for an average of 11.8 months compared with 6.9 months for patients on standard treatment.Trodelvy is available in India through various generic medication suppliers and the Trodelvy injection price in India is pocket-friendly, and anyone with a prescription can purchase it easily.

It's important to note that the best treatment for HER2-positive metastatic breast cancer will depend on the individual patient's medical history, tumor characteristics, and other factors. Patients should discuss all treatment options with their healthcare providers to make an informed decision about their care.

[techninja]

Shaping the Future of Cancer Care: Antibody Drug Conjugates Market Dynamics and Trends

Introduction

The Antibody Drug Conjugates (ADCs) market is a dynamic and rapidly growing sector in the pharmaceutical and biotechnology industries. ADCs represent a novel approach to cancer therapy, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. This synergy has led to significant advancements in the treatment of various cancers, and the market is witnessing a surge in research, development, and investment. In this article, we will delve into the Antibody Drug Conjugates market, exploring its current state, key players, challenges, and future prospects.

Understanding Antibody Drug Conjugates

Antibody Drug Conjugates are a class of targeted therapies designed to deliver cytotoxic drugs directly to cancer cells while sparing healthy tissues. The concept is elegantly simple: a monoclonal antibody is engineered to recognize and bind to a specific antigen expressed on the surface of cancer cells. This antibody is then conjugated to a potent cytotoxic drug, creating a highly selective and effective therapeutic agent.

Current Market Landscape

The ADC market has been steadily growing over the past decade, and it is projected to continue its upward trajectory. One of the primary drivers of this growth is the increasing prevalence of cancer worldwide. As the global cancer burden rises, there is an urgent need for more effective and less toxic treatments, making ADCs an attractive option.

Key Players and Developments

Several pharmaceutical and biotechnology companies have made significant investments in ADC research and development. Key players in the ADC market include Roche, Seattle Genetics, Immunomedics (now part of Gilead Sciences), and Daiichi Sankyo. These companies have brought several ADCs to market and have a robust pipeline of candidates in various stages of development.

One of the groundbreaking developments in the ADC field is the approval of Trodelvy (sacituzumab govitecan-hziy) by the U.S. Food and Drug Administration (FDA) in 2020. Trodelvy, developed by Immunomedics, has shown remarkable efficacy in treating triple-negative breast cancer and metastatic urothelial cancer, marking a significant milestone in ADC therapy.

Challenges and Opportunities

Despite the promising potential of ADCs, there are several challenges that the market faces. One of the primary challenges is the complexity of ADC development. Designing and manufacturing these molecules requires a deep understanding of antibody engineering, linker chemistry, and drug payload selection. Additionally, the regulatory landscape for ADCs is evolving, which can pose hurdles in the approval process.

Another challenge is the cost of ADC therapy. These drugs are often expensive, and there is a need for greater accessibility to ensure that patients can benefit from this advanced treatment. As more ADCs gain approval and competition increases, there is hope that pricing may become more competitive.

The future of the ADC market holds immense promise. Advancements in antibody engineering, linker technology, and drug payloads are expected to improve the safety and efficacy of ADCs. Moreover, ongoing research is exploring the potential of ADCs in treating a broader range of cancer types and even other diseases beyond oncology.

Conclusion

The Antibody Drug Conjugates market is a dynamic and evolving sector in the field of cancer therapy. With a growing number of ADCs gaining approval and a robust pipeline of candidates, there is a sense of optimism about the future of cancer treatment. As researchers and pharmaceutical companies continue to innovate, the potential for ADCs to revolutionize the way we approach cancer therapy remains high. While challenges persist, the progress made in this field is a testament to the dedication of scientists and the hope they bring to cancer patients worldwide. As we look ahead, the Antibody Drug Conjugates market is poised to play a pivotal role in the fight against cancer, offering new possibilities for improved patient outcomes and quality of life.

[your-dietician]

Gilead's Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer - Gilead Sciences (NASDAQ:GILD)

New Post has been published on https://medianwire.com/gileads-trodelvy-under-fda-review-for-pre-treated-hr-her2-metastatic-breast-cancer-gilead-sciences-nasdaqgild/

Gilead's Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer - Gilead Sciences (NASDAQ:GILD)

The FDA has accepted for review Gilead Sciences Inc’s GILD Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer.

The supplemental application covers patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

The target action date of the Prescription Drug User Fee Act (PDUFA) is February 2023.

Related: Gilead’s Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings.

The application is based on data from the registrational Phase 3 TROPiCS-02 study. In the study, Trodelvy demonstrated a 34% reduction in the risk of disease progression or death and a 21% decrease in the risk of death compared to chemo.

The safety profile for Trodelvy in TROPiCS-02 was consistent with prior studies, with no new safety concerns identified in this population.

Any regulatory agency has not approved Trodelvy for HR+/HER2- metastatic breast cancer. 

Price Action: GILD shares are up 2.34% at $65.97 on the last check Tuesday.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read full article here

[medicaltrend]

UK NICE recommended rejecting Gilead's Trodelvy treatment for triple-negative breast cancer.

[pharmaphorumuk]

The top 5 pharma M&A deals of 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values.

That said, there were still some interesting moves indicating new directions of travel for big pharma players – with most deals focused on specific drugs from biotechs, particularly in cancer (though we did get rumours of an AstraZeneca-Gilead merger, which would have been the biggest pharma M&A deal of all time).

Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.

AstraZeneca & Alexion

By far the biggest pharma deal of the year is AstraZeneca’s late-breaking offer to buy Alexion for $39 billion.

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and with the purchase, AZ will bolster its immunology franchise with $4 billion blockbuster Soliris (eculizumab) and longer acting follow-up Ultomiris (ravulizumab), plus a pipeline of 11 drugs for rare and autoimmune diseases.

It marks something of a departure from AZ’s relentless focus on deal-making in oncology, its top product category, and also comes as Alexion has been locked in a battle with activist shareholders pushing for a sale.

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

The threat of biosimilar competition to its cash cow has weakened Alexion’s share price, providing an opportunity for AZ, which has been rumoured to be angling for a large acquisition for several months.

While the first biosimilars to Soliris have already reached the market in some countries like Russia, Alexion cut a settlement deal with Amgen in the summer that prevents the latter’s biosimilar version of Soliris from entering the US market until 2025, avoiding a near-term cash cliff.

In the meantime, Ultomiris has been gathering momentum, fuelled by intravenous dosing every eight weeks, rather than every two weeks with Soliris. It racked up $340 million in sales last year, and added another $763 million in the first nine months of this year, backing up its blockbuster credentials.

Meanwhile, AZ will also pick up three other drugs – Strensiq (asfotase alfa) for hypophosphatasia, Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency (LAL-D) and anticoagulant reversal agent Andexxa (andexanet alfa) – that collectively brought in almost $675 million in the first nine months of 2020.

Gilead & Immunomedics

The AZ-Alexion deal is likely to be the only big pharma merger this year, but Gilead’s purchase of US biotech Immunomedics and its potential cancer blockbuster Trodelvy isn’t far off it in terms of value, with the deal totalling $21 billion.

California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 billion buy of Kite Pharma and followed that earlier this year by acquiring immuno-oncology firm Forty Seven for $4.9 billion (see below). Shoring up its assets in a wider range of disease areas will help the company weather the storm as the pool of patients eligible to receive its hepatitis C drugs such as Sovaldi shrinks.

Trodelvy (sacituzumab govitecan) is a first-in-class TROP2 antibody-drug conjugate drug that was granted accelerated approval by the FDA in April for adults with metastatic triple-negative breast cancer (TNBC), who have received at least two previous therapies for metastatic disease.

Data from trials of the drug wowed ESMO in September – Trodelvy was shown to significantly extend overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared with standard chemotherapy in TNBC patients with brain metastases treated with at least two therapies.

The 500-plus patients in ASCENT had received a median of four previous anticancer treatments, but Trodelvy significantly improved OS with a median of 12.1 months, compared with 6.7 months in patients treated with chemotherapy.

Johnson and Johnson & Momenta

This $6.5 billion deal means that J&J has added potential inflammatory disease blockbuster nipocalimab to the pipeline at its Janssen pharmaceuticals unit.

J&J thinks that Momenta’s lead drug nipocalimab could be a kind of Swiss army knife drug that could be used across a range of inflammatory diseases including maternal-foetal disorders, neuro-inflammatory disorders, rheumatology, and autoimmune haematology.

The success of AbbVie’s Humira (adalimumab), which peaked at almost $20 billion in sales in 2018, demonstrates the potential of inflammatory diseases drugs to make mega-bucks.

Johnson & Johnson’s own Remicade (infliximab) was also a blockbuster several times over thanks to approvals in a range of inflammatory diseases including Crohn’s, rheumatoid arthritis and psoriasis.

But like the rest of this first generation of antibody-based drugs, Remicade has been hit by cheaper competition from biosimilars and the hunt is on for newer drugs that outperform standard therapy in terms of safety and efficacy.

Whether nipocalimab achieves the astronomical figures seen from Humira and Remicade remains to be seen – but the price J&J has paid shows the big pharma thinks it has considerable potential.

Momenta is best known for producing a generic version of Teva’s multiple sclerosis drug Copaxone (glatiramer), but nipocalimab is the company’s lead pipeline asset and the main rationale behind the acquisition.

“The first wave had disproportionate health, economic and social impacts on people in lower socioeconomic groups and those with black, Asian and minority ethnic backgrounds”

Gilead & Forty Seven

Further cementing Gilead’s ambitions in cancer, this $4.9 billion deal adds an antibody targeting several blood cancers to the company’s research pipeline.

Forty Seven is based in Menlo Park, a short drive away from Gilead’s base in Foster City, and is developing magrolimab, which is targeting myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL).

A potential first-in-class therapy, magrolimab targets CD47, which produces a “do not eat me” signal that allows cancer cells to avoid destruction (an area AbbVie has almost invested significantly in).

By targeting CD47 it’s hoped that magrolimab will allow the patient’s own innate system to engulf and eradicate cancer cells.

The company presented promising results from a phase 1b study of magrolimab in patients with MDS and AML at the American Society of Hematology meeting in December.

Sanofi & Principia Biopharma

Sanofi added a potential multiple sclerosis drug to its pipeline when it bought Principia Biopharma for up to $3.68 billion in August.

The French pharma paid $100 per share in cash for San Francisco-based Principia, which specialises in Bruton’s kinase (BTK) inhibitor drugs, after the deal was unanimously agreed by both boards of directors.

Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017.

In a statement Sanofi said that the acquisition will give it full control of the brain-penetrant BTK inhibitor SAR442168, making marketing more efficient and eliminating any royalty payments due under the 2017 agreement.

The drug known for short as ‘168 reduced multiple sclerosis brain lesions by 85% compared with placebo in a phase 2b trial.

Phase 3 development has begun and will comprise four pivotal trials across the MS disease spectrum.

Another of Principia’s BTK inhibitors, rilzabrutinib, is being tested in phase 3 for patients with moderate to severe pemphigus, a rare and debilitating autoimmune disease that causes blistering of the skin and mucous membranes.

Principia also has a topical BTK inhibitor, PRN473, which is in phase 1 development for immune diseases that could benefit from local application to the skin.

The deal follows Sanofi’s announcement late last year that it is rethinking its R&D operations, turning its back on diabetes and focusing on badly needed “transformative” therapies and maximising the potential of its asthma and eczema drug Dupixent.

CEO Paul Hudson, who was appointed to the role in June last year, has already acquired the oncology firm Synthorx and signed a potential $2 billion collaboration with Kymera Therapeutics to develop immune-inflammatory drugs.

The post The top 5 pharma M&A deals of 2020 appeared first on .

from https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/

[ericvick]

Gilead Stock: Is It A Buy After Dumping Its Arthritis Drug Onto Galapagos?

Biotech company Gilead Sciences (GILD) makes an approved coronavirus treatment, but conflicting reports of the drug’s effectiveness haven’t helped Gilead stock.

X

Doctors successfully treated President Donald Trump with Gilead’s remdesivir — now known by the brand name Veklury — when he was diagnosed with Covid-19. In November, fellow drugmaker Eli Lilly (LLY) gained emergency authorization for a coronavirus treatment.

Still, in October the World Health Organization said Veklury had little or no effect on death rates of Covid-19 patients. And, last month, a top intensive care doctor said Veklury shouldn’t be used routinely in critical care wards.

In addition, its September announcement of what would be its largest acquisition ever — $21 billion for cancer drug maker Immunomedics — has weighed on Gilead stock. In December, Gilead announced it would buy MYR GmbH, a German biotech focused on hepatitis treatments.

So, should investors consider buying Gilead stock right now?

A Fundamental Look At Gilead Stock

Shares have been volatile through its remdesivir coronavirus treatment efforts. Gilead stock has fallen 9.4% in 2020 as of midday Dec. 16. Gilead stock is trading barely above seven-year lows, after touching a 21-month high of 85.97 in March.

Besides its coronavirus efforts, Gilead is trying to stake its claim in HIV treatments. It’s facing off against an outlet mostly owned by GlaxoSmithKline (GSK) called ViiV Healthcare.

Also, Gilead is pushing into cancer drugs with the takeovers of biotech companies Forty Seven, Kite Pharma and now Immunomedics. It’s also signed a collaboration deal with Arcus Biosciences (RCUS).

Gilead used to be a powerhouse in treating hepatitis C.

The drug called Sovaldi gained Food and Drug Administration approval in 2013. The following year, it raked in $10.3 billion in sales. Gilead also had success with drugs dubbed Harvoni and Epclusa. About 95% of hepatitis C patients can now be cured with treatment.

In 2016, hepatitis C drug sales tumbled 23% as the number of cures increased. That trend has persisted ever since despite the addition of a new hepatitis C drug known as Vosevi.

Gilead Sciences Earnings Expected To Rise Again

In the wake of that hepatitis C drug sales cliff, earnings have mostly painted a dim picture. That looked to turn around in the third quarter. Then, earnings popped 29% to $2.11 per share. Sales rose 17% to $6.58 billion.

But the earnings release didn’t help Gilead stock as shares lost 2.2% on the report.

Analysts polled by FactSet expect another rebound in the fourth quarter. On average, they expect Gilead to report adjusted earnings of $1.73 per share on $6.43 billion in sales, up a respective 33% and 9% year over year.

Still, Gilead stock isn’t completely lining up with CAN SLIM rules for investing. Investors should look for stocks with 20%-25% or better earnings and sales growth in the most recent quarter.

Taking into account fundamental and technical measures, Gilead stock had a weak Composite Rating of 41 as of Dec. 16, according to IBD Digital. That puts shares in the bottom half of all stocks.

Annual Metrics: What Does 2019 Tell Us?

In 2019, Gilead earnings were $6.63 per share, minus certain items. That edged down a fraction on a year-over-year basis. Operating cash flow came out to $6.69 per share — less than 1% ahead of profit. The fastest-growing companies have operating cash flow at least 20% above earnings per share.

But sales inched up 1% to $22.45 billion. That was the first time sales rose since 2015.

Less bullishly, Gilead’s annual pretax margin hit 47.6% — its lowest in six years. Pretax margin also slowed for the fourth year running. When looking for strong stocks, it’s smart to consider those with accelerating pretax margins.

In 2020, analysts polled by FactSet expect Gilead to earn $6.61 per share on $23.7 billion in sales. Earnings would climb by 4% and sales 5%.

GILD Stock Technical Analysis: No Chart Pattern

Shares of Gilead stock are currently trading below their 50-day and 200-day moving averages.

Gilead has an RS Rating of just 5, meaning its shares have outperformed just 5% of stocks over the last 12 months. Leading stocks tend to have RS Ratings of 80 or above.

Gilead stock ranks just No. 166 out of 636 publicly traded biotech stocks by Composite Rating in IBD’s Stock Checkup. Keep tabs on those scores by visiting IBD Digital.

Which Mutual Funds Are Investing In Gilead?

Slightly more funds increased their GILD stock positions last quarter vs. those that cut their holdings, 1,133 vs. 991.

For now, Gilead stock has an Accumulation/Distribution grade of B-, meaning more institutional investors are buying than selling shares.

GILD Stock News: Coronavirus Treatment Gets FDA Nod

In May, the Food and Drug Administration granted Gilead an emergency use authorization for the drug now called Veklury. Gilead’s coronavirus treatment officially gained approval in October.

Physicians can administer remdesivir intravenously each day for five days or 10 days in patients hospitalized with Covid-19.

In late June, Gilead set a $3,120 price tag for U.S. commercial patients in need of its coronavirus treatment. The price tag for patients not covered by private insurance is $2,340. Those prices undercut more bullish expectations.

The Institute for Clinical and Economic Review, which examines the value of drugs, put a fair price for the coronavirus treatment at $4,500, RBC Capital Markets analyst Brian Abrahams said in a report. A week earlier, remdesivir gained conditional marketing authorization in Europe.

Will GILD Stock Fly On Coronavirus Treatment?

In an open letter from Chief Executive Daniel O’Day on Oct. 8, Gilead reported its data on Covid-19 patients recovering on average five days faster with remdesivir, and seven days faster for the most seriously ill. Gilead sells the drug under the band name Veklury.

Moreover, O’Day wrote that remdesivir reduced the likelihood of patients progressing to more severe stages of the disease where they would require new or additional oxygen support. And he wrote that in the largest group of patients in the study, those on low-flow oxygen, there was a significant reduction in mortality in a post-hoc analysis.

That day, the company said the New England Journal of Medicine published final results from a U.S. National Institute of Allergy and Infectious Diseases Phase 3 trial showing Veklury “resulted in consistent, clinically meaningful improvements across multiple outcome assessments compared with placebo in Covid-19 patients.

“The final results demonstrate that treatment with Veklury resulted in a faster time to recovery than previously reported,” Gilead said in a news release.

But just a week later, the WHO reported that remdesivir appeared to have little or no effect on hospitalized Covid-19 patients, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.

2 Million Treatment Courses Of Veklury

Also on Oct. 8, Gilead announced a new supply deal with the European Union for its remdesivir, and GILD stock edged higher. Gilead said it’s on pace to produce more than 2 million treatment courses of Veklury this year.

On Oct. 5, GILD stock rose 2.3% on the news that President Trump had received remdesivir over the previous days after contracting Covid-19.

Gilead stock also edged higher more than 1% on Sept. 14, after the company announced its $21 billion acquisition of Immunomedics. That company’s drug Trodelvy recently received accelarate approval from the FDA to treat adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies.

Also helping shares on Sept. 14 was the announcement of positive clinical trials data by Eli Lilly and partner Incyte (INCY) for their Covid-19 treatment candidate combined with remdesivir. They said they would seek U.S. FDA emergency use authorization for the treatment.

Other Gilead Stock News

On Aug. 19, GILD stock fell 4.9% after the company announced the FDA’s unexpected decision to seek two more years of data for the company’s rheumatoid arthritis drug, known as filgotinib.

But Gilead stock rose 1% on Sept. 28 after European officials approved filgotinib as a treatment for rheumatoid arthritis. It’s sold under the brand name Jyseleca.

On Dec. 15, Gilead said it wouldn’t seek FDA approval for filgotinib as a rheumatoid arthritis treatment. It also transferred primary responsibility in Europe to its partner, Galapagos (GLPG).

Gilead stock jumped in early March after the biotech company announced its $4.9 billion plan to buy Forty Seven, a cancer-focused player. Forty Seven is testing an immuno-oncology drug in blood cancers and solid tumors.

In 2017, Gilead spent $11.9 billion to acquire Kite Pharma, the maker of Yescarta, a CAR-T drug. CAR-T drugs also target cancer by training the immune system.

So, Is Gilead Stock A Buy?

Based on CAN SLIM investing principles, the short answer is no. Gilead stock is not a buy right now based on the metrics that other big winning stocks showed at the beginning of major price runs.

Investors should look for stocks that beat expectations while growing sales and earnings.

Shares of GILD stock currently aren’t forming a clear pattern or consolidation, as of Dec. 16, according to MarketSmith.com.

(Related: See stocks near a buy zone.)

It will be key to watch for data from additional studies of Veklury in coronavirus treatment, including its possible use in combination with other drug therapies. Also, it’s testing an inhaled version, and other studies remain ongoing.

Is it time to buy or sell these other large-cap stocks? Keep tabs on IBD analysis.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Looking For Growth? Take A Look At These Biotechnology Stocks

Join IBD Live For Stock Ideas Each Morning Before The Open

Is Gilead’s Coronavirus Drug On Track To Become A Mega-Blockbuster?

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

[trodelvy]

Trodelvy price in india | 9310090915

Trodelvy, featuring the active ingredient sacituzumab govitecan, is crucial for treating metastatic triple-negative breast cancer, especially after two prior treatments. It combines a Trop-2-directed antibody with a topoisomerase inhibitor, and is prescribed when surgery isn’t an option. Trodelvy must be prescribed by licensed professionals. It is available and trodelvy price in India is affordable. You can contact us for more information.

Trodelvy: Lyophilized Powder Formulation Trodelvy is administered as per FDA guidelines, with dosages based on patient weight. The drug, sacituzumab govitecan-hziy, comes as a lyophilized powder, reconstituted with 0.9% sodium chloride to a 10 mg/mL concentration. Typically, 10 mg/kg is given intravenously on days 1 and 8 of a 21-day cycle. It comes as 180 mg and 200 mg packing. Trodelvy price in India is competitive and accessible through us, ensuring affordability for patients.

[sknews7]

Merger Monday Confirms An Active Stock Market – Buy Under-Appreciated Biotech

Mergers have been lagging

Mergers for 2020 have vastly lagged final yr. This has been a explanation for concern for me in judging the well being of the inventory market. For the raison d’etres of Wall Avenue is to not make us wealthy, it is to create a supply of fairness capital to construct firms. Our function will be in comparison with the remora fish that safe themselves to the leviathans and eat the wealthy the rest that they go away behind. Although our function is a little more symbiotic as we do provide liquidity, value discovery and thru the blessings of the brief vendor we current a stage of policing to stop the occasional “Theranos” that occurs every now and then. The inventory market didn’t come about for our amusement or enrichment. If it is not creating true transactions like M&A and public choices it is sickly and that doesn’t portend nicely for us remoras or the better economic system.

So I heartily accepted yesterday’s “Merger Monday” information. The torrent and dimension of the offers give me optimism that regardless of authorities intervention into our economic system and markets, the underlying mechanism is returning to life. There is a very actual chance that there will likely be a rush of mergers earlier than the shut of the yr both due to feared tax adjustments or the economic system is returning to a bustling boil. Why do I say that? Effectively, this coming quarter could be very prone to show the quickest development the economic system ever measured. Additionally, you might not have observed however revenue estimates are going up slightly properly, thanks very a lot. So with rates of interest at zero for so far as the attention can see, biotech, which bases its worth manner out sooner or later, because the promised stream of income are sometimes on the come, low rates of interest are extra welcome to this sector than the cloud software program world. I imagine that with the proof of yesterday’s mergers, particularly the astoundingly well-priced buy of Immunomedics (IMMU) by Gilead, that that is an space that ought to be speculated upon. Biotech’s time has come as soon as once more.

Gilead (GILD) forking out with a 108% excessive bid for Immunumedics (IMMU) for $21 billion: Recreation changer!

Biotech has been comparatively quiescent. We’ve all been enamored of the WFH motion (meaning “Work From House” for you modern-day Rip Van Winkles). Meaning demand for the likes of Zoom (ZM) and Amazon (AMZN) and never IBB, the Biotech ETF. Immunomedics’s new drug Trodelvy works on triple unfavorable breast most cancers, however the modality for effecting the remedy is the holy grail of most cancers remedy. Sure, I mentioned remedy, remedy is on supply, not 100%, however the chance is there. Let me insert a caveat right here. I‘m lower than knowledgeable on biotech. I hate that I can’t get my arms round it. So I do know there are numerous of you on the market who will remark under “how I don’t know what I am speaking about,” or that there are many different biotechs that even have the identical functionality. Good and high-quality, however you’re the blessed 2% with PHDs or MSs or you’ve spent the final decade poring over Lancet or NEJM, or no matter. I salute you, and you might deposit your derision within the remark part under. I am providing you with what I believe your on a regular basis dealer who pauses 60 seconds to consider what simply occurred yesterday and what it means for the biotech sector for them. OK?

So this is what I imply. IMMU has mainly developed a guided missile of remedy. They recognized a protein that is on the most cancers cell. Their drug is an antibody focusing on that protein on one facet and on different finish is a substance that is poisonous to the cell. Once they meet – kaboom. Meaning even cells that metastasize at a clump of even two, three cells, and even one will be focused. Maybe at a while there will likely be a number of protein targets, and easy blood exams that floor most cancers earlier than it may even be seen by present diagnostics. We simply had the submitting of an IPO for Grail Biotech that may just do that. In any case IMMU is thrilling and GILD bought them for a straightforward 108% above the final shut.

In yesterday’s CNBC interview GILD’s CEO intimated that whereas Tradelvy has been authorized for triple neg breast most cancers it has broad purposes to different cancers like lung most cancers strong tumors.

Trodelvy offered nicely in its first two months in the marketplace. As well as there was Sunday’s name to analysts. Gilead chief medical officer Merdad Parsey mentioned that his firm has seen unpublished information on Trodelvy that implies the drug will likely be of use towards a broad vary of strong tumors, together with bladder and lung cancers. Trodelvy’s gross sales in breast most cancers would widen, too, if it will get approval as a first-line remedy for tumors that present drug-resistant genetic traits

The primary response by analysts and market commentators was a wringing of arms and gnashing of enamel.

We heard a bunch of the naysayers say nay yesterday. I do not agree. GILD is anticipating the acquisition to be accretive to earnings by 2023. So even with out future indications IMMU will contribute to earnings in three years. Three years is the standard return on funding for gear. That is in my thoughts an astounding cut price. As well as, I am saying that biotech is simply too low cost total and that there must be different bargains on the market. Extra on that later. So let me defend GILD a bit additional. They’ve $15 billion in money proper now mendacity round doing nothing. It could actually’t even earn curiosity. So actually the acquisition is $5 billion that will likely be borrowed basically for nothing. I do know, I do know, you as a shareholder need that $15 billion. You need that in dividends or inventory buybacks? No you don’t. GILD is uniquely suited to do what most of us can’t – sift by way of all of the dross of biotech fly specs and floor those which can be value an funding. You additionally know that present authorized medication whereas throwing off astounding ranges of money are a losing asset quickly to be relegated to the generic drug pile. So that you don’t need that money. You need them to place that money to work. I for one am very excited by this information. So I purchased GILD and I believe it has plenty of room to run. Take a look at this one yr chart here.

That little fuschia arrow on the best is the place GILD is now. The large mountain of beneficial properties to the left was as a result of pleasure over Remdesivir which remains to be very a lot alive, and can have an additional function to play in combating COVID-19. In actual fact, yesterday we heard information that Eli Lilly (LLY) and incyte (INCY) are introducing a drug working with Remdesivir that provides to optimistic results for restoration. Olumiant is a particular immuno suppressant in a phase-Three research, on the lookout for emergency use approval from the FDA.

That apart, since I am a dummy with regards to choosing out up-and-coming biotechs, I am investing within the medium-sized biotech consolidators like GILD, but in addition Bristol Myers (BMY) that simply acquired Celgene, and Abbvie (ABBV) that simply purchased Allergan. I imagine that they are going to purchase smaller tuck-in acquisitions that may present extra beta. Within the meantime they throw off a pleasant dividend whilst you wait. They’re all in my funding account that I by no means speak about, as a result of I intend to purchase and maintain them without end. Nonetheless, I believe GILD will likely be a runner now, and so I’ve it in my hypothesis account as nicely.

Lest I neglect there was different main M&A information yesterday

Merck (NYSE:MRK) invested $1 billion in Seattle Genetics (SGEN) Antibody blood conjugates. Additionally this bizarre improvement with TikTok that I’m undecided tips on how to categorize, and the very attention-grabbing Nvidia (NVDA) information about buying ARM Holdings for $40B, (see under). Let’s additionally not neglect that Verizon (NYSE:VZ) purchased TracFone for a cool $9B whew!

Oracle (ORCL) might have bitten off greater than it may chew

There was a feeding frenzy over the acquisition of TikTok. Apparently the idea is that TikTok has an AI that may do it higher than anybody else. What occurs if they’re flawed? What occurs if that is only a random “fad?” By fad I imply that youngsters which can be amazingly fickle have determined that TikTok is the bee’s knees, like they determined that Snapchat was scorching at one level.

I believe it is the expansion, TikTok DAU shot up like loopy, so everybody assumes its the algorithm

It’d simply be a fad. I believe that is what Oracle is relying on, that they might rise up an AI algo that’s “adequate.” I will say “watch out what you want for” – ORCL might have bitten off greater than it may chew. Just like the canine chasing the automotive and eventually catches it – then what?

Possibly fad is not the best phrase. It caught on, and due to the community impact it’ll have endurance till it would not. Nonetheless it is not being categorized as an acquisition, and I am not even certain the deal they submitted with CFIUS will get authorized. I might be cautious about leaping on ORCL. I purchased on the rumor and offered it earlier than the information. I might be flawed, but when it isn’t a full acquisition and so they have to face up a working AI back-end for it, it might be a really thankless job.

In an identical vein, I believe Nvidia’s (NVDA) ARM Holdings acquisition is a “no bueno” as nicely

On this case the worth of ARM itself just isn’t in query. It was a jewel when Masayoshi Son stole it, and will probably be so when NVDA tries to accumulate it. I imagine there are large antitrust points, sovereign points with the UK, and China will take years to approve. This may be an equally large distraction for NVDA and at its present lofty (although justified) valuation. I see a hazard of a giant deflation in its worth as uncertainty creeps in because the deal drags on.

One of many founders of ARM, Hermann Hauser, mentioned he and lots of others have been involved that the UK would lose jobs and affect and argued ARM’s enterprise mannequin could be compromised. He acknowledged, “Surrendering UK’s strongest commerce weapon to the US is making Britain a US vassal state,” Hauser wrote within the open letter, which was revealed yesterday.

He referred to as on Boris Johnson to pressure Nvidia to signal legally-binding phrases agreeing to protect UK jobs, keep ARM’s market neutrality, and safe exemptions from US guidelines that will ban ARM from coping with China. If the UK authorities can’t safe these commitments, Hauser mentioned it ought to help an IPO of ARM on the London Inventory Change. I believe NVDA has opened a nasty can of worms. In fact if NVDA does crater, you’ll hear me shouting from the rooftops to purchase, purchase, purchase.

Talking of which, what did I purchase yesterday…

I began a place in Vroom (VRM) like I mentioned I might. I purchased a bunch of SPACs which I am not able to reveal proper now. SPACs have simply turn out to be so nuts that I would like to jot down a chunk simply to speak about them. I am constructing a place in Rocket Mortgage (RKT), extra on that tomorrow. Additionally like I mentioned I am making a speculative place in GILD along with my funding. I additionally rolled my Draft Kings (NASDAQ:DKNG) calls up and out to February liberating some premium after which spreading them as soon as once more to hopefully generate additional income by Oct. 2.

Disclosure: I’m/we’re lengthy VRM. I wrote this text myself, and it expresses my very own opinions. I’m not receiving compensation for it (aside from from Looking for Alpha). I’ve no enterprise relationship with any firm whose inventory is talked about on this article.

Further disclosure: I began a place in VRM, RKT and GILD. I additionally rolled my DKNG place up and out to February, and re-spread with brief calls and an Oct 2 expiry

window.SA = {"App":{"name":"SA","fullName":"Seeking Alpha","type":"regular","host":"https://seekingalpha.com","financeApiHost":"https://finance.api.seekingalpha.com","emailHost":"https://email.seekingalpha.com","pro":false,"proPlus":false,"contributorCenter":false,"realHostName":"https://seekingalpha.com","isCms":false,"cancelPV":false,"isSharkPreview":false,"usersOnSite":"8,909,032","assetHosts":["https://static.seekingalpha.com","https://static1.seekingalpha.com","https://static2.seekingalpha.com","https://static3.seekingalpha.com"],"moneData":{"params":"new_home_page=new_hpu0026samw_layout=hybrid"},"assetHost":"https://static.seekingalpha.com","userEchoHost":"https://feedback.seekingalpha.com","unbounceHost":"https://subscriptions.seekingalpha.com","env":{"dev":false,"staging":false,"production":true,"test":false},"gaAccountId":"UA-142576245-1","pianoAccountId":"CWJjPp7cpu","comscoreAccountId":8500672,"fbAppId":"2459764930747368","googleClientId":"853676697728-j4qpq4pfialt14ibl9ppa3tk37m6kc9e.apps.googleusercontent.com","twitterAccountName":"SeekingAlpha","rollbarToken":"5edf110be2fc4cecb32637fc421111e2","perimeterXAppId":"PXxgCxM9By","embedlyKey":"a6da93fdfc49472099ce63260954716b","mp":false,"chat":{"host":"https://rc.seekingalpha.com"},"oneSignalAppId":"32a623ea-4435-442f-a7e1-0ef070124c32","gptHeaderTest":null,"allowAdBlockPopup":null},"pageConfig":{"Refresher":{"active":false},"Data":{"article":{"id":4374418,"title":"Merger Monday Confirms An Active Stock Market - Buy Under-Appreciated Biotech","stub":false,"primaryTicker":"","indexGroup":null,"prioritizedTicker":"gild","primaryIsCrypto":null,"isTranscript":false,"isSlides":false,"twitContent":"Merger Monday Confirms An Active Stock Market - Buy Under-Appreciated Biotech. https://seekingalpha.com/article/4374418-merger-monday-confirms-active-stock-market-buy-under-appreciated-biotech?source=tweet ","isProArticle":false,"isProPaywall":false,"paywallReason":null,"isArchived":false,"editorsPicks":false,"inEmbargo":false,"isAuthorNewsletter":false,"titleTest":null,"archiveOn":0.0,"isProNoEmbargo":false,"url":"https://seekingalpha.com/article/4374418-merger-monday-confirms-active-stock-market-buy-under-appreciated-biotech","isFreeMpArticle":false,"isInsight":false,"insightSlug":"","price_at_publication":null,"date_at_publication":null,"closest_trading_day":"2020-09-15","isArticleInTradingTime":true,"themes":["portfolio-strategy-asset-allocation","sa-exclusive","us","article"],"from_liftigniter":false,"isAnyProArticle":false,"allowMpPromotion":false,"article_datetime":"2020-09-15T13:15:00.000-04:00","date_epoch":"1600142400","isEtf":true,"taggedUrlsHtml":"u003cspanu003eu003ca href="https://seekingalpha.com/analysis/etf-portfolio-strategy/all" sasource="article_navigation"u003eu003cspanu003eETFs u0026 Portfolio Strategyu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/etf-portfolio-strategy/portfolio-strategy-asset-allocation" sasource="article_navigation"u003eu003cspanu003ePortfolio Strategy u0026 Asset Allocationu003c/spanu003eu003c/au003eu003c/spanu003e","isFidelityEducationPage":false,"isSponsored":false,"contentData":null,"marketingBullet":null,"showPastPodcast":false,"publishDate":"2020/09/15","symbolType":null,"symbolExchange":null,"accessReason":false,"excludedByTag":false},"author":{"id":105256,"userId":43755796,"slug":"david-h-lerner","exclusiveResearch":null,"tagId":599385,"name":"David H. Lerner","picture_url":"https://static.seekingalpha.com/images/users_profile/043/755/796/big_pic.png","is_brand_author":false,"show_managed_account":false,"is_tier1":false},"comments":{"discussion_status":0,"discussion_message":"Comments disabled for this article"},"brand":null,"firstResearchAuthor":{},"pageType":"article","primaryTickerRtaCount":"0","articleModeratedMsg":null,"indexTickers":{},"authorSentiment":[],"themesSubscriprionsCounter":{"daily-dispatch":"227,786","macro-view":"252,172","sectors":"26,371","global-markets":"56,310","wall-st-breakfast":"718,008","investing-ideas":"297,001","etf-content-once-daily-newsletter":"138,265","alternative-energy-once-daily-newsletter":"108,125","transcripts":"14,369","activity-alerts-daily-newsletter":"3,230,051","activity-alerts-weekly-newsletter":"72,420","investing-income":"230,361","tech-daily-newsletter":"107,365","authors-alerts":"93,117","ipo-analysis":"83,917","ma-daily":"17,913","must-read":"1,410,211"}},"Ads":{"slots":[{"container":"article-left-slot-2","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":160},"size":[[160,600],"fluid"],"str":"160x600,fluid"}},{"container":"article-left-slot-3","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":162},"size":[[160,600],"fluid"],"str":"160x600,fluid"},"delay":true,"whenOutOfView":"article-left-slot-2","sticky":true},{"container":"article-right-slot-1","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":1},"size":[[300,250],[300,600],[300,1050],"fluid"],"str":"300x1050,300x250,300x600,fluid"},"cls":"mb25","flex":true},{"container":"article-right-slot-2","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":100},"size":[[300,100],[300,26],"fluid"],"str":"300x100,300x26,fluid"},"cls":"mb25"},{"container":"article-right-slot-3","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":2},"size":[[300,252],"fluid"],"str":"300x252,fluid"},"cls":"mb25","native":true},{"container":"article-middle-slot-1","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{},"size":[[640,40]],"str":"640x40"}},{"container":"ad_728x90","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":728},"size":[[728,90],[970,250],"fluid"],"str":"728x90,970x250,fluid"},"delay":true,"delta":500},{"container":"pushdown_top_ad","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":970},"size":[[970,250],[728,90],"fluid"],"str":"728x90,970x250,fluid"}},{"container":"instream_recommendation_ad","data":{"name":"/6001/sek.analysis/investing-strategy/portfolio-strategy","disable_collapse_empty_div":false,"targeting":{"tile":50},"size":["fluid"],"str":"fluid"},"delay":true,"delta":500}],"testScroll":true,"disabled":false,"kvs":{"d":["analysis","etfs"],"t":["investing-strategy","portfolio-strategy-asset-allocation","sa-exclusive","us","article"],"aid":"4374418","mp_free_article":"false","a":"david-h-lerner","cnt":["9","21","6","8","24","oil","etrfin","fed","taxes","nra","tech","bny","ssga6","jh1","fnk1","fnk2","port","nw1","19","fnk3","loan","NYL1","br_list","fnk7","fnk10","fnk12","wf13","wf14","wf15","wf17","wf18","fnk14t"],"ldr":"market-outlook","s":["gild","abbv","amzn","bmy","bmymp","immu","incy","lly","nvda","orcl","rkt","sgen","vrm","zm"],"ab_new_home_page":"new_hp","ab_samw_layout":"hybrid"}},"Paths":{"int":{"adsAPI":{"src":"https://static.seekingalpha.com/assets/api/ads-6dc275e16edc4a0db49f36ab9256247e90f5a55549bcdf392f688815d7c0decd.js","id":"sa-ads-api"}},"ext":[{"src":"https://www.googletagservices.com/tag/js/gpt.js","id":"gpt"},{"src":"https://js-sec.indexww.com/ht/p/183642-175291741781218.js","id":"ie"},{"src":"https://sb.scorecardresearch.com/beacon.js","id":"sb"},{"src":"https://www.googletagmanager.com/gtm.js?id=GTM-PFXR76F","id":"gtm"},{"src":"https://connect.facebook.net/en_US/sdk.js","id":"facebook-jssdk"}]},"lastRequested":"2020-09-15 14:31:58 -0400","SlugsPrices":{"disabled":false},"saSource":null,"name":"article","useSQuoteSource":"iex"},"headerConfig":{"noNotificationsMenu":null,"nonFixed":null,"tabless":null,"activeTab":null},"modules":{},"requires":[],"trackq":[],"exceptions":[],"gptInit":false}; Source link

from WordPress https://ift.tt/3iLlpKk via IFTTT

[trodelvy]

Buy Trodelvy 180 mg Injection at Lowest Price from India

Trodelvy 180 mg for injection is designed to carry cancer-fighting drug to cells that have Trop-2 proteins. Certain tumor cells have high Trop-2 proteins. The medicine trodelvy 180 mg injection is approved for 3 different types of cancer:

Advanced Bladder Cancer

HR+/HER2- Metastatic Breast Cancer

Metastatic Triple Negative Breast cancer Trodelvy injection 180 mg is a type of antibody-drug conjugate (ADC) treatment that is designed to work differently than traditional chemotherapy. It is designed to deliver promising anticancer drug directly into cells with Trop-2 proteins. Make an inquiry either via TOLL-FREE: 1800-889-1064, or Call/WhatsApp: +919310090915 and we will help you compute the total price to buy Trodelvy (sacituzumab govitecan) for injection online at the best price and have it delivered to your location. From your side, we’ll only need a valid prescription from your treating physician. In some countries, we might also ask for an import license.

[trodelvy]

All You Need to Know About Trodelvy and Its Therapeutic Advancements

In the landscape of oncology, advancements in targeted therapies continue to reshape the way we approach and treat various types of cancer. One such groundbreaking therapeutic drug is Trodelvy (sacituzumab govitecan-hziy), a novel antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer (mTNBC), hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and metastatic urothelial cancer (mUC).

Approved by the FDA, Trodelvy offers hope to patients facing limited treatment options, demonstrating promising efficacy and tolerability in clinical trials.

Understanding Trodelvy: Trodelvy is a first-in-class antibody-drug conjugate (ADC) designed to selectively target and deliver chemotherapy to cancer cells expressing the Trop-2 receptor. Trop-2 is overexpressed in a variety of solid tumors, including triple-negative breast cancer, HR-positive/HER2-negative breast cancer, and urothelial cancer, making it an attractive target for therapy. The medicinal product is supplied for injection: 180 mg lyophilized powder in single-dose vials for reconstitution for intravenous use.

Indications for Use: Trodelvy 200 mg injection is indicated for the treatment of: Metastatic Triple-Negative Breast Cancer (mTNBC): This therapeutic drug is approved for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least two prior systemic therapies for metastatic disease. HR-positive/HER2-negative Metastatic Breast Cancer: The medicine is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) in patients who have received two or more prior systemic therapies. Metastatic Urothelial Cancer (mUC): Trodelvy is also approved for patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Dosage and Administration: Trodelvy is administered intravenously under the supervision of a healthcare professional (HCP). The recommended dosage and treatment regimen may vary depending on the type of cancer being treated and the patient's individual characteristics.

Trodelvy is typically administered at a recommended dosage of 10 mg/kg via intravenous infusion once weekly, specifically on Days 1 and 8 within a 21-day treatment cycle. Treatment should be continued until disease progression or if any adverse reactions become unacceptable. It's essential not to exceed the recommended dosage of 10 mg/kg. Close monitoring for potential adverse reactions is essential during treatment with Trodelvy.

How Trodelvy Works: Trodelvy utilizes a two-part mechanism of action to target and destroy cancer cells:

Targeted Delivery: The monoclonal antibody component of Trodelvy binds specifically to the Trop-2 receptor, which is overexpressed on the surface of cancer cells. This targeting mechanism allows Trodelvy to selectively deliver the attached chemotherapy payload to cancer cells while sparing healthy tissues.

Chemotherapy Payload: Once bound to the Trop-2 receptor, Trodelvy is internalized by the cancer cell, releasing its payload of the chemotherapy drug, SN-38. SN-38 is a potent inhibitor of topoisomerase I, an enzyme essential for DNA replication and cell division. By inhibiting topoisomerase I, SN-38 induces DNA damage and ultimately leads to cancer cell death.

Clinical Efficacy: Clinical trials evaluating Trodelvy have demonstrated promising results in patients with metastatic triple-negative breast cancer and metastatic urothelial cancer. In a pivotal Phase 3 trial in mTNBC, Trodelvy significantly prolonged progression-free survival and overall survival compared to standard chemotherapy. Similarly, in a Phase 2 trial in mUC, Trodelvy showed durable responses and favorable survival outcomes in patients who had previously received platinum-based chemotherapy and immunotherapy.

Side Effects: While Trodelvy offers significant therapeutic benefits, it can also cause side effects. Common side effects associated with Trodelvy may include: Neutropenia: Treatment with this medication can cause a decrease in white blood cell counts, specifically neutrophils, which can increase the risk of infection. Diarrhea: Gastrointestinal symptoms such as diarrhea may occur and should be managed promptly to prevent dehydration. Nausea and Vomiting: Some patients may experience nausea and vomiting during treatment with Trodelvy. Fatigue: Fatigue or weakness may occur as a result of treatment.

It is essential for patients to communicate any side effects or symptoms to their healthcare provider promptly.

Precautions and Considerations: While Trodelvy offers significant therapeutic benefits, it is essential to consider precautions and potential risks associated with its use. Patients receiving Trodelvy should be monitored closely for adverse reactions, including: Hepatotoxicity: Trodelvy can cause liver damage, as indicated by elevated liver enzymes. Liver function tests should be performed regularly, and patients with pre-existing liver conditions should be closely monitored. Interstitial Lung Disease (ILD): ILD, including pneumonitis, can occur with Trodelvy treatment. Patients should report any new or worsening respiratory symptoms, such as cough or difficulty breathing, to their healthcare provider promptly. Pregnancy and Breastfeeding: Trodelvy can harm an unborn baby and should not be used during pregnancy. Women of childbearing age should use effective contraception during treatment and avoid breastfeeding.

It is crucial for healthcare providers to assess patients' medical history and closely monitor for potential complications during Trodelvy treatment. Patients should be educated about the importance of reporting any adverse reactions or symptoms to their healthcare provider promptly. By carefully considering precautions and taking appropriate measures, patients and healthcare providers can maximize the benefits of Trodelvy while minimizing risks.

Cost of Trodelvy: At present, Trodelvy (sacituzumab govitecan) is not currently available in India. However, it's important to note that prices can fluctuate based on variables such as dosage and treatment duration. For the most accurate and current information regarding the cost of Trodelvy in India, Patients, Doctors, and Hospitals are encouraged to reach out to Indian Pharma Network (IPN) via Call/WhatsApp: +91 9310090915.

Conclusion: Trodelvy represents a significant advancement in the treatment of breast cancer and urothelial cancer, offering a targeted and effective therapy for patients who have progressed on standard treatments. By understanding the indications, mechanism of action, clinical efficacy, and potential side effects associated with Trodelvy, patients and healthcare providers can make informed decisions about treatment options and optimize patient outcomes. Continued research and clinical trials will further elucidate the role of Trodelvy in the evolving landscape of cancer therapy.

Reference:

[trodelvy]

Trodelvy for Patients in India: What You Need To Know

Introduction:

Trodelvy (sacituzumab govitecan-hziy) is a medication prescribed for specific cancer types. Administered intravenously, it's typically infused as a solution mixed from a powder, given on days 1 and 8 within a 21-day treatment cycle for adults with certain cancers in specific scenarios. Trodelvy is used in adults to treat the following cancers in certain situations:

Triple-negative breast cancer (TNBC)

HR-positive, HER2-negative breast cancer

urothelial cancer (cancers affecting the urinary tract, such as certain bladder cancers)

Sacituzumab govitecan-hziy is the key component of Trodelvy, a member of the antibody-drug conjugate drug class. As a biologic medication, Trodelvy is derived from living cells, distinguishing it from traditional chemical-based drugs.

Trodelvy (sacituzumab govitecan-hziy) for Indian Patients: Sacituzumab govitecan, an FDA-approved therapeutic drug, combines a Trop-2-directed antibody with a topoisomerase inhibitor drug conjugate. With 3 established indications, it's a recommended treatment by oncologists for metastatic triple-negative breast cancer, HR-positive, HER2-negative breast cancer, and metastatic urothelial cancer. Gilead Sciences developed and promotes this therapeutic drug, known by its brand name Trodelvy, with a commercially available strength of 180 mg per vial.

Sacituzumab or Trodelvy in India is not readily accessible from local pharmacies or oncology centers. This is because the medicinal product is yet to be locally registered. However, Indian patients have an official provision called the Named Patient Program (NPP) through which patients can procure the medication. The internationally authorized commercial vials can be sourced on behalf of medical advice. Oncologists are known to prescribe specialized medicines for various approved indications even though they are not promptly available. Patients can readily source or procure those medications by applying for the relevant permits from India.

Access Trodelvy (sacituzumab govitecan-hziy) in India: Professional Guidance If you're an Indian patient looking for Trodelvy 180 mg price in India, the Indian Pharma Network (IPN) is here to help. We have years of experience in assisting patients like you with getting advanced medicines such as Sacituzumab govitecan 180 mg in India. Our process is straightforward and ensures that you feel comfortable every step of the way. We'll connect you with trusted sources who can help speed up the import process for your therapeutic drug. We know how important it is to get lifesaving drugs quickly, and our team is dedicated to helping you get the treatment you need as soon as possible.

Contact Indian Pharma Network today for all your medical needs. Reach out via Call/WhatsApp: +91 9310090915 or dial our TOLL-FREE number: 1800-889-1064 for assistance.

Reference: https://www.trodelvy.com/

[trodelvy]

Trodelvy for Breast Cancer

TRODELVY is a cancer drug which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer and locally advanced or metastatic urothelial cancer (mUC). It is a trop-2-directed antibody and topoisomerase inhibitor conjugate drug used at prescribed and recommended doses according to body weight. It is given intravenously only, and the Trodelvy injection price is economical, and it can be bought by any recognized supplier. It is given in the vein by drip on day 1 and day 8 of the repeating 3-week cycle. Treatment may be continued for as long as it remains effective. It has the active ingredient, Sacituzumab govitecan, which is responsible for the action of Trodelvy by attaching to the antibody by the linker.

TRODELVY: Dosage and Administration It comes as 180 mg lyophilized powder in single-dose vials for reconstitution to be given intravenously. It is given on the basis of weight, and the recommended dose is 10 mg/kg, administered as an IV infusion once weekly. It is also available in 200mg vials, and we supply TRODELVY 200 mg vials at Ikris against a valid prescription. Before administering Trodelvy, antipyretic medication is given to the patient to induce nausea and vomiting, which are caused due to an infusion reaction. Antipyretic drugs act as H1 and H2 blockers, and those who have prior infusion reactions are given corticosteroids. After premedication, Trodelvy is given for 3 hours intravenously; during and after 30 minutes, any kind of infusion-related reactions are observed.

TRODELVY: Availability In India Trodelvy has been compared with standard treatment in one of the main studies, which had 529 patients with metastatic or locally advanced triple-negative breast cancer who received two or more prior systemic (whole-body) treatments, including at least one of them for advanced disease. Patients who took Trodelvy lived for an average of 4.8 months without cancer progression and getting it worse than as compared with 1.7 months for the patients who took standard treatment. Patients on Trodelvy lived for an average of 11.8 months compared with 6.9 months for patients on standard treatment. Trodelvy is available in India through various generic medication suppliers and the TRODEDLVY injection price in India is pocket-friendly, and anyone with a prescription can purchase it easily.

TRODELVY: Mechanism of action The active pharmaceutical ingredient in Trodelvy is Sacituzumab govitecan-hziy which consists of two active components that are a monoclonal antibody ( which is a kind of protein ) that has been linked to a small molecule, SN-38. The monoclonal antibody has been made to recognize and attach to Trop-2(a kind of protein in many breast cancer cells). When it is attached, and the drug is used up by the cell, then SN-38 becomes active. SN-38 is a cancer medicine that belongs to the group topoisomerase inhibitors. It blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and eventually die. Trodelvy's benefits are greater than its risks; that's why it is approved by FDA, and anyone with a prescription can buy trodelvy in India.

TRODELVY: Adverse Drug Reaction Like any other medication, it comes with some undesired side effects. The most common side effect caused by taking Trodelvy is diarrhea, Nausea (feeling of being sick), low count of neutrophils( they are a kind of WBC which help to fight against infection), loss of hair which is called alopecia, anaemia ( low levels of haemoglobin, causes pale skin and tiredness ). These common ADRs affect more than 1 in 5 people who are undergoing the treatment. Other common side effects include loss of appetite, constipation, cough, belly pain and vomiting. Vomiting and Nausea can also occur during the time of infusion, so to prevent these, antipyretics are given as premedication. The most common serious side effects are febrile neutropenia which is low white blood cell counts with fever due to infection and diarrhea. Well, this medication is all safe to use and is FDA approved. Moreover, the cost of Trodelvy in India is economical and budget-friendly, and it should be used under the influence of expert medical supervisors of its speciality.

TRODELVY: Measures to ensure safe and effective use While preparing in an infusion bag, a sterile syringe is used in order to preserve aseptic practice and make the preparation safe from any kind of contamination. Do not shake, but gently swirl. It is light-sensitive, so it needs to be protected from light and must be stored in cool and shady places. After mixing, if there is any precipitation or cloudy substance forming, don't use the preparation and discard it. As for all medicines, data on the use of Trodelvy are continuously monitored. Predicted side effects reported with Trodelvy are carefully evaluated, and any necessary action is taken to protect patients. One can ask his pharmacist or healthcare provider for information about TRODELVY that is written for health professionals. During intravenous infusion, too, the patient must be carefully observed. Trodelvy injections are available, and the cost of trodelvy injection is budget friendly as compared to other medications of the same line.

[trodelvy]

Trodelvy: Revolutionizing TNBC Treatment Dosage, Administration, and Economic Perspectives

Trodelvy, also known as sacituzumab govitecan, represents a groundbreaking medication that has brought new hope to cancer treatment. Its approval for use in adults grappling with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) after at least two prior systemic treatments marks a significant milestone.

Indication Trodelvy's approval by regulatory agencies signals a pivotal moment in oncology. Classified as an antibody-drug conjugate, it works by delivering potent chemotherapy directly to cancer cells, minimizing damage to healthy cells. Its target, the Trop-2 receptor often elevated in TNBC, makes it a selective treatment. The administration involves intravenous infusion weekly on Days 1 and 8 of a 21-day cycle,continuing until disease progression or intolerable toxicity occurs.

Dosage And Administration

Trodelvy, in 180 mg and 200 mg single-dose vials, is given intravenously at 10 mg/kg weekly on Days 1 and 8 of a 21-day cycle, weight-adjusted. Vials stored at 2°C to 8°C should reach room temperature before reconstitution with 20 mL of 0.9% sodium chloride, yielding 10 mg/mL. Avoid shaking; gently swirl. Premedicate for infusion-related nausea. Initial infusion may take 3 hours, followed by 30 minutes of post-infusion monitoring. Subsequent infusions last 1-2 hours, with 30 minutes of post-infusion observation. Dose adjustment or cessation may occur for specific side effects.

Trodelvy Price in India The cost of Trodelvy varies based on dosage and treatment duration. Cancer treatments generally pose a significant financial burden due to complex development and specialized nature. In India, Trodelvy is priced economically, though it remains a substantial investment for patients. Nevertheless, the potential benefits it offers in terms of improved quality of life and extended survival rates often outweigh the financial considerations for many individuals.

[trodelvy]

Trodelvy for Breast Cancer

Trodelvy, also known as sacituzumab govitecan-hziy, is available in 180 mg and 200 mg dosages. Because of freeze-drying, this drug is delivered in single-dose vials that range in color from off-white to yellowish. Each vial is individually wrapped in a carton. One 180 mg vial with the packing code NDC 55135-132-01 is included. These vials must be stored in their original containers and chilled between 2 and 8 degrees Celsius. The drug shouldn't ever be frozen. Trodelvy needs to be handled and disposed of carefully because it can be harmful. Trodelvy therapy can also result in a variety of side effects, such as anemia, fatigue, baldness, decreased appetite, coughing, nausea, vomiting, and diarrhea.

Trodelvy is an essential component of triple-negative breast cancer (mTNBC) treatment for metastatic disease. Sacituzumab govitecan is the active ingredient that gives trodelvy its medicinal effects. The monoclonal antibody and the particular protein that make up this drug are essential components. Patients who have received at least two prior therapies for metastatic illness are the main beneficiaries of this treatment. When it is not possible to remove the malignant tissue surgically, trodelvy is used.Remember that only authorized medical experts are permitted to prescribe Trodelvy. To buy trodelvy in India and provide access to a larger population, contact Indian Pharma Network.

Trodelvy dosages are based on the patient's body weight and must be administered in compliance with FDA-approved cycles. Every repeating 21-day cycle, an intravenous dose of 10 mg/kg is administered twice a day, on the first and eighth day. Since sacituzumab govitecan-hziy is a lyophilized powder, dosage must be precisely determined by the patient's weight. The vial is combined with 20 mL of 0.9% sodium chloride injection, USP, to achieve a concentration of 10 mg/mL.Indian Pharma Network provides a fairly costly Trodelvy 180mg, which is easily accessible on the market.

A 5-HT3 receptor antagonist or an NK1 receptor antagonist is prescribed as a premedication in addition to dexamethasone as part of the therapy protocol. This premedication strategy reduces the likelihood of nausea and vomiting from chemotherapy and infusion responses. Trodelvy's special combination of an anti-Trop-2 antibody and a topoisomerase inhibitor accounts for its low cost in India. Corticosteroids should be administered to people whose prior infusions did not go well.Contact Indian Pharma Network a certified distributor of this medication, for more details on the rodelvy cost.

Patients with advanced triple-negative breast cancer who have received at least two prior therapy have hope with trodelvy. Its interaction with SN-38, a tiny molecule essential to its method of action, is what makes it effective. Trodelvy's monoclonal antibody's capacity to bind to the Trop-2 protein found on a variety of breast cancer cells contributes to the drug's efficacy. Trodelvy's affordability, which is made possible by Indian Pharma Network, is an added benefit. For those who are interested in learning more about the Trodelvy price. More than one in five patients with metastatic triple-negative breast cancer who are receiving medication may also have baldness, decreased appetite, coughing, stomach discomfort, and tiredness in addition to anemia.